Skip to Main Content

Paper Details

The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.
Clin Transl Sci
25
2022
Author NameAffiliation
Alexander P J VlaarUniversity of Amsterdam
  • 1 - 1

Datasets

Release 1.2